IL6 and ovarian cancer: Treatment with CX-4945 significantly reduced the constitutive release of TNF and IL6 was significantly reduced in the cell culture supernatant of five ovarian cancer cell lines that were cytokine producers after treatment with CX-4945 (Figure 3E) and VEGF production was also inhibited in 3/4 parental cell lines (Figure 3E).